In addition, for cancer patients, CK19-2G2 levels in patients with MBC (Mean = 7.96 mU/ml, SE = 1.96 mU/ml) were higher than those with stage I-III PBC (Mean = 2.61 mU/ml, SE = 0.23 mU/ml) (P = 0.007) and DCIS (Mean = 1.85 mU/ml, SE = 0.39 mU/ml) (P = 0.002) respectively. The gene discussed is KRT19; the disease is ductal breast carcinoma in situ.